American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) responses of patients with rheumatoid arthritis (RA) at weeks 6 and 30; patients are classified by low affinity and high affinity FCGR2A and FCGR3A genotypes
| FCGR2A | FCGR3A | |||||||||
| Total | HH-HR | RR | p Value | Total | VV-VF | FF | p Value | |||
| 6 weeks | ACR20 | 45.8% (38/83) | 43.6% (27/62) | 52.4% (11/21) | 0.483 | 44.6% (33/74) | 35.6% (16/45) | 58.6% (17/29) | 0.051 | |
| ACR50 | 12.1% (10/83) | 11.3% (7/62) | 14.3% (3/21) | 0.716 | 10.8% (8/74) | 2.2% (1/45) | 24.1% (7/29) | 0.003 | ||
| ACR70 | 3.6% (3/83) | 3.2% (2/62) | 4.8% (1/21) | 0.744 | 2.7% (2/74) | 2.2% (1/45) | 3.5% (1/29) | 0.751 | ||
| EULAR good response | 33.7% (29/86) | 32.3% (21/65) | 38.1% (8/21) | 0.630 | 31.2% (24/77) | 22.9% (11/48) | 44.8% (13/29) | 0.040 | ||
| EULAR good to moderate response | 68.6%(59/86) | 64.6% (42/65) | 81.0% (17/21) | 0.160 | 67.5% (52/77) | 64.6% (31/48) | 72.4% (21/29) | 0.480 | ||
| 30 weeks | ACR20 | 40.0% (32/81) | 33.3% (20/61) | 60.0% (12/20) | 0.035 | 40.0% (29/73) | 41.9% (18/44) | 37.9% (11/29) | 0.739 | |
| ACR50 | 15.0% (12/81) | 15.0% (9/61) | 15.0% (3/20) | 1.000 | 12.3% (9/73) | 11.6% (5/44) | 13.8% (4/29) | 0.785 | ||
| ACR70 | 2.5% (2/81) | 3.3% (2/61) | 0.0% (0/20) | 0.408 | 1.4% (1/73) | 2.3% (1/44) | 0.0% (0/29) | 0.408 | ||
| EULAR good response | 28.2% (24/85) | 25.0% (16/64) | 38.1% (8/21) | 0.250 | 26.0% (20/77) | 23.4% (11/47) | 30.0% (9/30) | 0.520 | ||
| EULAR good to moderate response | 61.2% (52/85) | 56.3% (36/64) | 76.2%(16/21) | 0.100 | 61.0% (47/77) | 57.4%(27/47) | 66.7%(20/30) | 0.420 | ||
Significant values are in bold.